TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a significant increase in short interest in May. As of May 15th, there was short interest totalling 109,000 shares, an increase of 206.2% from the April 30th total of 35,600 shares. Approximately 0.7% of the company's shares are short sold. Based on an average daily volume of 49,800 shares, the days-to-cover ratio is presently 2.2 days.
TriSalus Life Sciences Stock Up 4.2%
TLSI traded up $0.21 during trading hours on Monday, hitting $5.21. 31,154 shares of the company's stock were exchanged, compared to its average volume of 42,268. The stock has a market cap of $197.14 million, a price-to-earnings ratio of -2.09 and a beta of 0.50. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $7.55. The stock's 50-day moving average is $5.41 and its two-hundred day moving average is $5.10.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The business had revenue of $9.17 million for the quarter, compared to analysts' expectations of $9.04 million. During the same quarter in the previous year, the business earned ($0.60) earnings per share. On average, equities research analysts anticipate that TriSalus Life Sciences will post -1.55 EPS for the current year.
Insider Transactions at TriSalus Life Sciences
In related news, insider Richard Marshak sold 6,597 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the sale, the insider now owns 69,101 shares in the company, valued at $357,943.18. This represents a 8.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 16,125 shares of company stock valued at $83,528 over the last three months. 27.50% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On TriSalus Life Sciences
A number of institutional investors and hedge funds have recently made changes to their positions in TLSI. Goldman Sachs Group Inc. bought a new position in shares of TriSalus Life Sciences in the first quarter valued at $187,000. Charles Schwab Investment Management Inc. acquired a new stake in TriSalus Life Sciences in the first quarter valued at $55,000. Connective Capital Management LLC bought a new position in shares of TriSalus Life Sciences in the 4th quarter valued at about $140,000. Bridgeway Capital Management LLC grew its position in shares of TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock valued at $326,000 after acquiring an additional 50,000 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after purchasing an additional 178,298 shares during the last quarter. Institutional investors own 2.58% of the company's stock.
Analyst Ratings Changes
A number of research analysts have issued reports on TLSI shares. Lake Street Capital began coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 target price for the company. Canaccord Genuity Group restated a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, March 28th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $10.75.
Get Our Latest Analysis on TriSalus Life Sciences
TriSalus Life Sciences Company Profile
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Articles
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
